Canadian researchers open a new front in the fight against MS

A discovery led by scientists at the University of Alberta and McGill University is providing hope of a new therapeutic target in Multiple Sclerosis (MS) patients, which could one day be used to prevent the symptoms and progression of the disease.

The study "Calnexin is necessary for T cell transmigration into the central nervous system" was published in JCI Insight, was funded by the Canadian Institutes of Health Research.